WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1891-01-01

Employees: 10K

Market Cap: -

Website: http://www.medschool.wustl.edu

Clinical Trials

Intermittent Fasting in Multiple Sclerosis

Not Applicable

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Other: Intermittent fasting

First Posted Date: 2018-05-29

Last Posted Date: 2024-01-16

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 61

Registration Number: NCT03539094

Locations: 🇺🇸
Washington University in St Louis, Saint Louis, Missouri, United States

Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder

Phase 4

Terminated

Conditions: Depressive Disorder
Major Depressive Disorder
Depression
Depressive Episode
Depression, Unipolar

Interventions: Other: GeneSight Psychotropic test
Drug: FDA-approved antidepressant or antipsychotic treatment

First Posted Date: 2018-05-25

Last Posted Date: 2020-06-05

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 6

Registration Number: NCT03537547

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Dietary Assessment and Prevalence of Refeeding Syndrome in High-risk TB Patients in Chhattisgarh, India

Completed

Conditions: Severe Malnutrition
Tuberculosis
Refeeding Syndrome

First Posted Date: 2018-05-25

Last Posted Date: 2018-05-25

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 31

Registration Number: NCT03537170

Locations: 🇮🇳
Jan Swasthya Sahyog, Ganiyari, Chhattisgarh, India

Localization of Peripheral Pulmonary Lesions: A Pilot Study

Phase 1

Withdrawn

Conditions: Peripheral Lung Lesions

Interventions: Procedure: Conventional bronchoscopy
Device: VIDA Pulmonary Workstation 2
Procedure: Biopsy

First Posted Date: 2018-05-24

Last Posted Date: 2018-12-20

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT03536026

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Phase 1

Completed

Conditions: Metastatic Hormone-Sensitive Prostate Cancer

Interventions: Biological: PROSTVAC-V
Biological: PROSTVAC-F
Drug: Nivolumab
Drug: Ipilimumab
Biological: Neoantigen DNA vaccine
Device: TriGrid Delivery System
Procedure: Tumor biopsy
Procedure: Peripheral blood
Procedure: Fecal samples
Procedure: Leukapheresis

First Posted Date: 2018-05-22

Last Posted Date: 2022-08-05

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 19

Registration Number: NCT03532217

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Phase 2

Active, not recruiting

Conditions: Glioma
Glioblastoma

Interventions: Drug: Bevacizumab
Drug: Epacadostat
Radiation: Radiation therapy
Procedure: Peripheral blood draw
Drug: Retifanlimab

First Posted Date: 2018-05-22

Last Posted Date: 2024-08-05

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 51

Registration Number: NCT03532295

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States

Ocular Changes After Ivermectin - (DOLF IVM/Oncho)

Not Applicable

Completed

Conditions: Onchocerciasis

Interventions: Drug: Ivermectin 3Mg Tab

First Posted Date: 2018-05-07

Last Posted Date: 2020-12-31

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 231

Registration Number: NCT03517462

Locations: 🇬🇭
University of Health and Allied Sciences, Hohoe, Ghana

Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

Phase 1

Recruiting

Conditions: Rectal Cancer

Interventions: Drug: Epacadostat
Radiation: Short-course radiation therapy
Drug: CAPOX chemotherapy
Drug: FOLFOX chemotherapy

First Posted Date: 2018-05-04

Last Posted Date: 2024-11-13

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 49

Registration Number: NCT03516708

Locations: 🇺🇸
University of California Irvine - Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
Henry Ford Cancer Institute, Detroit, Michigan, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Remote Limb Ischemic Conditioning to Enhance Learning and Muscle Strength in Healthy Young Adults

Phase 1

Completed

Conditions: Healthy, Young Adults

Interventions: Behavioral: RLIC
Behavioral: Sham conditioning
Behavioral: Muscle strength training
Behavioral: Driving training
Behavioral: Balance training

First Posted Date: 2018-04-30

Last Posted Date: 2020-02-05

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 34

Registration Number: NCT03512028

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement

Phase 1

Completed

Conditions: Healthy, Young Adults

Interventions: Behavioral: RLIC - 5 cycles
Behavioral: RLIC - 4 Cycles
Behavioral: RLIC - 3 Cycles
Behavioral: Sham conditioning
Behavioral: Balance training
Behavioral: Arm training
Behavioral: Sequence production training

First Posted Date: 2018-04-30

Last Posted Date: 2019-08-26

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 40

Registration Number: NCT03512041

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy